Epidemiological and ethiopological features of urinary tract infections , current state of problem (literature review)

Authors

  • O.M. Gegliuk Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • I.M. Antonyan Kharkiv Medical Academy of Postgraduate Education, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.22.2.2018.135701

Keywords:

urinary tract infections, endotoxins, antibacterial therapy, complicated urinary tract infection, antibiotic resistance, recurrent

Abstract

Urinary tract infections (UTI) are a group of the most common bacterial infections. Every year in the world more than 150 million cases are registered. UTI occupy second place after respiratory infections. There are different systems of classification of UTI. The most widely used are those developed by the Centers for Disease Control and Prevention (CDC), the American Society for Infectious Diseases (IDSA), the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), and the US Food and Drug Administration (FDA). According to the recommendations of the AEA 2017, UTIs are distinguished: uncomplicated, complicated, recurrent, catheter-associated and urosepsis. The dominant etiology of E. coli – E. coli, which is identified in 70–95%, is S. saprophyticus in 5–10% of patients. Other pathogens (Proteus mirabilis, K.neumoniae, P.aeruginosa) are more characteristic of complicated urinary tract infections. UTIs are characterized by high virulence, adherence and endotoxicity, in connection with which this group of microorganisms is able to counteract antibacterial drugs and is characterized by a high rate of recurrence.

References

Б. Вюльт. Асимптоматическая бактериурия – ключ к врожденному иммунному ответу и иммуномодуляции при инфекции мочевых путей // Урологія. Нефрологія. Андрологія. – 2017. – № 1 (8).

W.E. Stamm, S.R. Norrby. Urinary Tract Infections: DiseasePanorama and Challenges. – 2001.

Перепанова Т.С., Палагин И.С. Актуальные вопросы терапии и профилактики урологических инфекций, стандарты и рекомендации по ведению пациентов с урологическими инфекциями // Вестник практического врача. – 2014. – № 3. – С. 14–17.

Nicolle L.E. Urinary tract infections in the elderly // Clin. Geriatr. Med. – 2009;25:423–36.

Rowe T.A., Juthani-Mehta M. Diagnosis and management of urinary tract infectionin older adults // Infect. Dis. Clin. North. Am. – 2014;28:75–89.

Griebling T.L. Urologic Diseases in America Project: trends in resource use for urinary tract infections in men // J. Urol. – 2005;173:1288–94.

Caljouw M.A.A., den Elzen W.P.J., Cools H.J.M., Gussekloo J. Predictive factors of urinary tract infections among the oldest old in the general population: a population-based prospective follow-up study // BMC Med. – 2011;9:57–64.

Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA) // Clin. Infect. Dis. – 1999;29(4):745–58.

Основні показники урологічної та нефрологічної допомоги в Україні за 1988 р. / П.Л. Павлова, Н.О. Сайдакова, Л.М. Старцева. – К., 1999. – 125 с.

Основні показники урологічної допомоги в Україні за 2007–2008 рр. / Н.О. Сайдакова, Л.М. Старцева, Н.Г. Кравчук. – К., 2009. – 192 с.

Основні показники урологічної допомоги в Україні за 2014–2015 рік. / Н.О. Сайдакова, Л. М. Старцева. – К., 2016. – 206 с.

Horan T.C. et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting // Am. J. Infect. Control. – 2008;36:309.

Rubin R.H. et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration // Clin. Infect. Dis. – 1992;15:216.

Rubin U.H.S.E. et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. The European Society of Clinical Microbiology and Infectious diseases. – Taukirchen, Germany, 1993. – 240 p.

U.S. Department of Health and Human Services, F.D.A., Center for Drug Evaluation and Research (CDER). Guidance for Industry Uncomplicated Urinary Tract Infections. — Developing Antimicrobial Drugs for Treatment, 1998.

U.S. Department of Health and Human Services, F.D.A., Center for Drug Evaluation and Research (CDER). Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry, 2015.

Johansen T.E. et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system // Int. J. Antimicrob. Agents. – 2011;38:64.

Grabe M., Bartoletti R., Bjerklund Johansen T.E. et al. Guidelines on urological infections. – 2015 (http://uroweb.org/wp-content/uploads/19-Urological-infections_LR2. pdf).

Naber K.G. et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy // Eur. Urol. – 2008;54:1164.

Ramakrishnan K., Scheid D.C. Diagnosis and management of acute pyelonephritis in adults // Am. J. Fam. Phys. – 2005;71(5):933–941.

Chatterjee S., Chaudhury S., McShan A.C., Kaur K., De Guzman R.N. Structure and biophysics of type III secretion in bacteria // Biochemistry. – 2013;52(15):2508–17.

Alteri C.J., Mobley H.L. Escherichia coli physiology and metabolism dictates adaptation to diverse host microenvironments // Curr. Opin. Microbiol. – 2012;15(1):3–9.

Vandewalle A. Toll-like receptors and renal bacterial infections // Chang Gung Med J. – 2008;31(6):525–37.

Nicolle L.E. Urinary tract infection: traditional pharmacologictherapies // Am. J. Med. – 2002;113:35-44.

Grude N., Tveten Y., Jenkins A., Kristiansen B.E. Uncomplicated urinary tract infections. Bacterial findings and efficacy of empirical antibacterial treatment // Scand. J. Prim. Health Care. – 2005;23(2):115–119.

Foxmann B., Barlow R., D’Arcy H. et al. Urinary tract infection: Self-reported incidence and associated costs // Ann. Epid. – 2000;10:509–515.

Dodd M.C., Stillman W.В. The in vitro bacteriostatic action of some simple furan derivatives // J. Pharmacol. Exp. Ther. – 1944;82:11–18.

PLoS ONE: Klebsiella pneumoniae Multiresistance Plasmid pMET1: Similarity with the Yersinia pestis Plasmid pCRY and Integrative Conjugative Elements.

Outbreak of Klebsiella pneumoniae producing a new. – Antimicrob Agents Chemother. – 2004.

Wiskur et al. Hypermucoviscosity as a Virulence Factor in Experimental Klebsiella pneumoniae Endophthalmitis. – Investigative Ophthalmology & Visual Science.

Антибіотикорезистентність та інфекційний контроль. Інформаційне управління Апарату Верховної ради України (http://www.rada.gov.ua).

Published

2018-06-27

Issue

Section

Review of literature